ATC code G02AD01 (WHO) PubChem CID 5280363 | CAS Number 551-11-1 Molar mass 354.48 g/mol | |
 | ||
AHFS/Drugs.com International Drug Names Routes of
administration Intravenous (to induce labor), intra-amniotic (to induce abortion) Biological half-life 3 to 6 hours in amniotic fluid, less than 1 minute in blood plasma | ||
Prostaglandin f2alpha
Prostaglandin F2α (PGF2α in prostanoid nomenclature), pharmaceutically termed dinoprost (INN), is a naturally occurring prostaglandin used in medicine to induce labor and as an abortifacient.
Contents
In domestic mammals, it is produced by the uterus when stimulated by oxytocin, in the event that there has been no implantation during the luteal phase. It acts on the corpus luteum to cause luteolysis, forming a corpus albicans and stopping the production of progesterone. Action of PGF2α is dependent on the number of receptors on the corpus luteum membrane.
The PGF2α isoform 8-iso-PGF2α was found in significantly increased amounts in patients with endometriosis, thus being a potential causative link in endometriosis-associated oxidative stress.
Mechanism of action
PGF2α acts by binding to the prostaglandin F2α receptor.
Synthesis
In 2012 a concise and highly stereoselective total synthesis of PGF2α was described. The synthesis requires only seven steps, a huge improvement on the original 17-steps synthesis of Corey and Cheng, and uses 2,5-dimethoxytetrahydrofuran as a starting reagent, with S-proline as an asymmetric catalyst.
Analogues
The following medications are analogues of prostaglandin F2α: